Expression of an antisense transforming growth factor-beta1 transgene reduces tumorigenicity of EMT6 mammary tumor cells.

Abstract:

:Transforming growth factor-beta (TGF-beta) is a potent immunosuppressive cytokine produced by many tumor cells. Secretion of TGF-beta by malignant cells may therefore be a mechanism by which tumor cells escape destruction by tumor-specific T lymphocytes. In order to evaluate the role of tumor-derived TGF-beta on tumor progression, we have inhibited the production of this cytokine by introducing a gene encoding antisense TGF-beta1 into the EMT6 murine mammary tumor cell line using a retroviral vector (Las-TGF-beta1SN). EMT6 cells transduced with this vector (EMT6as-TGF-beta1) stably expressed the antisense gene and secreted 52% less TGF-beta than did tumor cells transduced with the backbone vector alone. Supernatant fluid recovered from tumor cells expressing the antisense TGF-beta1 gene also exhibited a decreased capacity to inhibit alloantigen-specific cytotoxic T-cell responses in vitro. Furthermore, tumor growth in mice injected with EMT6as-TGF-beta1 tumor cells was inhibited compared to mice injected with control tumor cells. These results demonstrate that expression of antisense TGF-beta1 by transduced EMT6 cells decreases their tumorigenicity and suggest that this approach of eliminating immune suppression is a potentially useful strategy to enhance antitumor responses.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Park JA,Wang E,Kurt RA,Schluter SF,Hersh EM,Akporiaye ET

subject

Has Abstract

pub_date

1997-01-01 00:00:00

pages

42-50

issue

1

eissn

0929-1903

issn

1476-5500

journal_volume

4

pub_type

杂志文章
  • Bacterial vectors for imaging and cancer gene therapy: a review.

    abstract::The significant burden of resistance to conventional anticancer treatments in patients with advanced disease has prompted the need to explore alternative therapeutic strategies. The challenge for oncology researchers is to identify a therapy which is selective for tumors with limited toxicity to normal tissue. Enginee...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/cgt.2012.59

    authors: Cronin M,Stanton RM,Francis KP,Tangney M

    更新日期:2012-11-01 00:00:00

  • Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up.

    abstract::We present here the updated results after 9 years of the beginning of a trial on canine patients with malignant melanoma. This surgery adjuvant approach combined local suicide gene therapy with a subcutaneous vaccine composed by tumor cells extracts and xenogeneic cells producing human interleukin-2 and granulocyte-ma...

    journal_title:Cancer gene therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/cgt.2012.72

    authors: Finocchiaro LM,Glikin GC

    更新日期:2012-12-01 00:00:00

  • Synergistic tumor inhibition of colon cancer cells by nitazoxanide and obeticholic acid, a farnesoid X receptor ligand.

    abstract::The tumor-suppressive role of Farnesoid X receptor (FXR) in colorectal tumorigenesis supports restoring FXR expression as a novel therapeutic strategy. However, the complicated signaling network and tumor heterogeneity hinder the effectiveness of FXR agonists in the clinical setting. These difficulties highlight the i...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41417-020-00239-8

    authors: Yu J,Yang K,Zheng J,Zhao W,Sun X

    更新日期:2020-10-13 00:00:00

  • Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.

    abstract::The majority of human neuroblastomas express low to undetectable levels of major histocompatibility complex (MHC) class I and II antigens (MHC-I and -II). We studied the effects of gamma interferon (gamma-IFN) transduction on expression of these antigens in six human neuroblastoma cell lines with and without genomic a...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:

    authors: Uçar K,Seeger RC,Challita PM,Watanabe CT,Yen TL,Morgan JP,Amado R,Chou E,McCallister T,Barber JR

    更新日期:1995-09-01 00:00:00

  • Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation.

    abstract::To develop novel therapies for aggressive thyroid cancers, we have synthesized a collection of histone deacetylase (HDAC) inhibitor analogs named AB1 to AB13, which have different linkers between a metal chelating group and a hydrophobic cap. The purpose of this study was to screen out the most effective compounds and...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2015.37

    authors: Jang S,Yu XM,Odorico S,Clark M,Jaskula-Sztul R,Schienebeck CM,Kupcho KR,Harrison AD,Winston-McPherson GN,Tang W,Chen H

    更新日期:2015-08-01 00:00:00

  • Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.

    abstract::Expression of costimulatory molecules by recombinant poxviruses is a promising strategy for enhancing therapeutic vaccines. CD40-CD40L interactions are critical for conditioning dendritic cells (DC) and priming T- and B-cell immunity. We constructed a vaccinia virus expressing murine CD40L (rV-CD40L) and studied its i...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700762

    authors: Bereta M,Bereta J,Park J,Medina F,Kwak H,Kaufman HL

    更新日期:2004-12-01 00:00:00

  • Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.

    abstract::Neprilysin (neutral endopeptidase, NEP) is a cell surface peptidase whose expression is lost in approximately 50% of prostate cancers (PC). NEP normally functions to inactivate peptides such as bombesin and endothelin-1, and potentiates the effects of the PTEN tumor suppressor via a direct protein-protein interaction....

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7701047

    authors: Horiguchi A,Zheng R,Goodman OB Jr,Shen R,Guan H,Hersh LB,Nanus DM

    更新日期:2007-06-01 00:00:00

  • Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy?

    abstract::MicroRNAs (miRNAs) were discovered more than a decade ago as noncoding, single-stranded small RNAs (approximately 22 nucleotides) that control the timed gene expression pattern in Caenorhabditis elegans life cycle. A number of these evolutionarily conserved, endogenous miRNAs have been shown to regulate mammalian cell...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/cgt.2008.8

    authors: Tong AW,Nemunaitis J

    更新日期:2008-06-01 00:00:00

  • Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.

    abstract::Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a m...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700343

    authors: Densmore CL,Kleinerman ES,Gautam A,Jia SF,Xu B,Worth LL,Waldrep JC,Fung YK,T'Ang A,Knight V

    更新日期:2001-09-01 00:00:00

  • Intrabody targeting vascular endothelial growth factor receptor-2 mediates downregulation of surface localization.

    abstract::Angiogenesis is among the most important mechanisms that helps cancer cells to survive, grow and undergo metastasis. Therefore, inhibiting angiogenesis will suppress tumor growth. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are believed to be important players of angiogenesis. The goal of this s...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2016.76

    authors: Alirahimi E,Ashkiyan A,Kazemi-Lomedasht F,Azadmanesh K,Hosseininejad-Chafi M,Habibi-Anbouhi M,Moazami R,Behdani M

    更新日期:2017-01-01 00:00:00

  • Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding.

    abstract::The Ki-ras gene is frequently mutated and/or overexpressed in human cancer. Since it is suspected to play a key role in the pathogenesis of many tumors, there is interest to search for strategies aiming at the specific inhibition of this oncogene. In this paper, we investigated the capacity of a 20 mer G-rich oligonuc...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700722

    authors: Cogoi S,Ballico M,Bonora GM,Xodo LE

    更新日期:2004-07-01 00:00:00

  • Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors.

    abstract::p53 mutations are common genetic alterations in human cancer. Gene transfer of a wild-type (wt) p53 gene reverses the loss of normal p53 function in vitro and in vivo. A phase I dose escalation study of single intratumoral (i.t.) injection of a replication-defective adenoviral expression vector containing wt p53 was c...

    journal_title:Cancer gene therapy

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.cgt.7700214

    authors: Dummer R,Bergh J,Karlsson Y,Horowitz JA,Mulder NH,Huinink DTB,Burg G,Hofbauer G,Osanto S

    更新日期:2000-07-01 00:00:00

  • Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy.

    abstract::Chemotherapy remains the main tool for the treatment of cancers, but is often hampered by tumor cell resistance. In this context, the transfer of genes able to accentuate the effect of anticancer drugs may constitute a useful approach, as exemplified by inactivation of nuclear factor (NF)-kappa B via direct transfer o...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700467

    authors: Cherbonnier C,Déas O,Vassal G,Merlin JL,Haeffner A,Senik A,Charpentier B,Dürrbach A,Bénard J,Hirsch F

    更新日期:2002-06-01 00:00:00

  • Apatinib prevents natural killer cell dysfunction to enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma.

    abstract::Apatinib, a selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC). Preclinical and preliminary clinical results have confirmed the synergistic antitumor effects of apatinib in ...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41417-020-0186-7

    authors: Yang Y,Wang C,Sun H,Jiang Z,Zhang Y,Pan Z

    更新日期:2020-06-12 00:00:00

  • Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.

    abstract::Despite radical surgery and multi-agent chemotherapy, less than one third of patients with recurrent or metastatic osteosarcoma (OS) survive. The limited efficacy of current therapeutic approaches to target tumor-initiating cells (TICs) may explain this dismal outcome. The purpose of this study was to assess the impac...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2011.83

    authors: Rainusso N,Brawley VS,Ghazi A,Hicks MJ,Gottschalk S,Rosen JM,Ahmed N

    更新日期:2012-03-01 00:00:00

  • Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

    abstract::This study was performed with the aim to investigate the correlations of tumor necrosis factor-alpha (TNF-α) gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis (T-MG) in a northern Chinese Han population. Between June 2005 and June 2015, 305 MG patients (150 males and 155 females, MG gro...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2017.13

    authors: Yang HW,Lei P,Xie YC,Han ZL,Li D,Wang SH,Sun ZL

    更新日期:2017-06-01 00:00:00

  • E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.

    abstract::Combination therapy with replicative oncolytic viruses is a recent topic in innovative cancer therapy, but few studies have examined the efficacy of oncolytic adenovirus plus replication-deficient adenovirus carrying a suicide gene. We aim to evaluate whether an E1A, E1B double-restricted oncolytic adenovirus, AxdAdB-...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2008.67

    authors: Fukuda K,Abei M,Ugai H,Kawashima R,Seo E,Wakayama M,Murata T,Endo S,Hamada H,Hyodo I,Yokoyama KK

    更新日期:2009-02-01 00:00:00

  • Virotherapy clinical trials for regional disease: in situ immune modulation using recombinant poxvirus vectors.

    abstract::The ability of viruses to readily infect tumor cells both in vitro and in vivo has resulted in their study as antitumor agents through a variety of strategies. Replicating and conditionally replicating viruses and recombinant viruses encoding genes for toxins and/or prodrugs have been studied for their direct antitumo...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/sj.cgt.7700538

    authors: Mastrangelo MJ,Lattime EC

    更新日期:2002-12-01 00:00:00

  • Inhibition of Gli2 suppresses tumorigenicity in glioblastoma stem cells derived from a de novo murine brain cancer model.

    abstract::The prognosis of glioblastoma remains poor despite intensive research efforts. Glioblastoma stem cells (GSCs) contribute to tumorigenesis, invasive capacity, and therapy resistance. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), a stem cell marker, is involved in the maintenance of GSCs, although ...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/s41417-020-00282-5

    authors: Tanigawa S,Fujita M,Moyama C,Ando S,Ii H,Kojima Y,Fujishita T,Aoki M,Takeuchi H,Yamanaka T,Takahashi Y,Hashimoto N,Nakata S

    更新日期:2021-01-07 00:00:00

  • Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas.

    abstract::Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines,...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700110

    authors: Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

    更新日期:2000-02-01 00:00:00

  • Lipid-coated polyplexes for targeted gene delivery to ovarian carcinoma cells.

    abstract::A nonviral gene delivery vector has been developed in our laboratory based on the cationic polymer, poly(2-(dimethylethylamino)ethyl methacrylate) (p(DMAEMA)). p(DMAEMA)-based polyplexes have been successfully used for the transfection of OVCAR-3 cells in vitro. However, these polyplexes were unable to transfect OVCAR...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700311

    authors: Mastrobattista E,Kapel RH,Eggenhuisen MH,Roholl PJ,Crommelin DJ,Hennink WE,Storm G

    更新日期:2001-06-01 00:00:00

  • Enhanced target gene knockdown by a bifunctional shRNA: a novel approach of RNA interference.

    abstract::RNA interference (RNAi) is a natural cellular regulatory process that inhibits gene expression by transcriptional, post-transcriptional and translational mechanisms. Synthetic approaches that emulate this process (small interfering RNA (siRNA), short hairpin RNA (shRNA)) have been shown to be similarly effective in th...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2010.35

    authors: Rao DD,Maples PB,Senzer N,Kumar P,Wang Z,Pappen BO,Yu Y,Haddock C,Jay C,Phadke AP,Chen S,Kuhn J,Dylewski D,Scott S,Monsma D,Webb C,Tong A,Shanahan D,Nemunaitis J

    更新日期:2010-11-01 00:00:00

  • Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

    abstract::Aberrantly expressed microRNAs (miRNAs) are involved in breast tumorigenesis. It is still unclear if and how miRNAs-221/222 are implicated in breast cancer and the resistance to estrogen receptor modulator tamoxifen. We investigated the roles and mechanisms of miR-221/222 in breast cancer cells, particularly in modula...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2014.29

    authors: Gan R,Yang Y,Yang X,Zhao L,Lu J,Meng QH

    更新日期:2014-07-01 00:00:00

  • Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

    abstract::Prostate cancer is one of the most commonly diagnosed cancers and the second leading cause of cancer deaths in Americans. The high mortality rate is mainly attributed to the invasiveness and metastasis of advanced prostate cancer. Targeting the molecules involved in metastasis could be an effective mode of treatment f...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/cgt.2010.16

    authors: Nalla AK,Gorantla B,Gondi CS,Lakka SS,Rao JS

    更新日期:2010-09-01 00:00:00

  • Suppressor of cytokine signaling-1 expression by infectivity-enhanced adenoviral vector inhibits IL-6-dependent proliferation of multiple myeloma cells.

    abstract::Multiple myeloma (MM) accounts for 10% of hematological malignant disorders. Its refractory nature indicates the necessity of developing novel therapeutic modalities. Since interleukin 6 (IL-6) is one of the major growth factors for MM cells, we expressed suppressor of cytokine signaling-1 (SOCS-1), one of the blockad...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700873

    authors: Yamamoto M,Nishimoto N,Davydova J,Kishimoto T,Curiel DT

    更新日期:2006-02-01 00:00:00

  • Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

    abstract::Drug metabolizing transgene products, which activate bioreductive cytotoxins, can be used to target treatment-resistant hypoxic tumors. The prodrug AQ4N is bioreduced in hypoxic cells by cytochrome P450s (CYPs) to the cytotoxin AQ4. Previously we have shown that intra-tumoral injection of CYP3A4 and CYP2B6 transgenes ...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700933

    authors: Yakkundi A,McErlane V,Murray M,McCarthy HO,Ward C,Hughes CM,Patterson LH,Hirst DG,McKeown SR,Robson T

    更新日期:2006-06-01 00:00:00

  • Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model.

    abstract::Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The present study explored the possibility of preventing ovarian cancer metastasis by promoting nm23H1 expression through adeno-associated virus (AAV)-mediated gene transfer. ...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700899

    authors: Li J,Zhou J,Chen G,Wang H,Wang S,Xing H,Gao Q,Lu Y,He Y,Ma D

    更新日期:2006-03-01 00:00:00

  • Zinc fingers and homeoboxes family in human diseases.

    abstract::The zinc-fingers and homeoboxes (ZHX) family is a group of nuclear homodimeric transcriptional repressors that interact with a subunit of nuclear factor-Y (NF-YA) and contain two C2H2-type zinc fingers and five homeobox DNA-binding domains. The members of ZHX family form homodimers or heterodimers with other members o...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/cgt.2015.16

    authors: Liu Y,Ma D,Ji C

    更新日期:2015-05-01 00:00:00

  • Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.

    abstract::Gene therapy for prostate cancer may be realized through transduction of whole genes, such as PSA or PSMA, into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed. Remarkably, tran...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章

    doi:10.1038/sj.cgt.7700810

    authors: Medin JA,Liang SB,Hou JW,Kelley LS,Peace DJ,Fowler DH

    更新日期:2005-06-01 00:00:00

  • MicroRNA and drug resistance.

    abstract::Chemotherapy is the preferred treatment for malignancies. However, a successful long-term use of chemotherapy is often prevented by the development of drug resistance. Many mechanisms such as gene mutation, DNA methylation and histone modification have important roles in the resistance of cancer cells to chemotherapeu...

    journal_title:Cancer gene therapy

    pub_type: 杂志文章,评审

    doi:10.1038/cgt.2010.18

    authors: Ma J,Dong C,Ji C

    更新日期:2010-08-01 00:00:00